|
????:2015??4??17??湲?-18???? ????: BEXCO, 遺�??/p> 二?理?:?�?쒖떖?ν븰?? ?쒓뎅?ы룷?뚰뙆?숉쉶, ?�?쒖떖?덇?以묒옱?숉쉶, ?쒓뎅吏�吏??숇㎘寃쏀솕?숉쉶 ?덊럹?댁?: http://www.circulation.or.kr/workshop/2015spring/ [?�?쒖떖?ν븰?? [?쒓뎅?ы룷?뚰뙆?숉쉶] [?�?쒖떖?덇?以묒옱?숉쉶] [?쒓뎅吏�吏??숇㎘寃쏀솕?숉쉶]
| Interesting ECG [April 17, 09:15-10:45 Rm.103]
|
|
| Chairperson |
|
| Speakers |
源�?좊━/?몄궛?섎?, 臾명씗???쒕┝?섎?, 諛뺤?踰??곗꽭?섎?, ?좎듅??以묒븰?섎?,
?꾩옱???곗꽭?섎?, 議곗쁺吏??쒖슱?섎? |
| Myocardial Infarction 1 [April 17, 09:30-10:45
Rm.104] |
|
| How to Analyze and Write Good Papers From a
Big Registry Data |
| Chairperson |
|
| Panel |
|
| 09:30-09:45 |
Sharing Experiences: How to Analysis Data From
KORMI/KAMIR |
?섏듅??怨좊젮?섎? |
| 09:45-10:10 |
Analysis of HIRA-Claim Data |
TBA |
| 10:10-10:35 |
Dealing With Confounding in the Analysis of Registry
Data |
?ㅼ꽦泥??몄궛?섎? |
| 10:35-10:45 |
Discussion |
| CHF 1 [April 17, 09:30-10:45 Rm.201] |
|
| Advanced Heart Failure ; Clinical
Challenges |
| Chairperson |
|
| Panel |
|
| Panel |
|
| 09:30-09:50 |
Coronary CT and Calcium CT ? The Resolution for
Cardiovascular Screening |
理쒖긽???쒖슱?섎? |
| 09:50-10:10 |
Echocardiography for Screening in Preoperative and
High-risk Subjects |
源�?�寃??깃퇏愿�?섎? |
| 10:10-10:30 |
SPECT or PET for Cardiovascular Screening in High-risk
Subjects |
TBA |
| 10:30-10:45 |
Discussion |
| Arrhythmia 1 [April 17, 10:55-12:20 Rm.103] |
|
| Facts and Truth |
| Chairperson |
|
| Panel |
|
| 10:55-11:20 |
CFAE Ablation: Absolute or Obsolete Procedure? |
?ㅼ슜??媛�?⑤┃?섎? |
| 11:20-11:45 |
End Points of AF Ablation |
?쒖꽦??怨꾨챸?섎? |
| 11:45-12:15 |
What We Have Learned About AF From Catheter
Ablation |
Jonathan Kalman/
Melbourne Univ.,
Australia |
| 12:15-12:20 |
Discussion |
| Myocardial Infarction 2 [April 17, 10:55-12:20
Rm.104] |
|
| Specific Issues of AMI
Treatment |
| Chairperson |
|
| Panel |
|
| 10:55-11:15 |
How to Manage STEMI in Very Elderly Patients |
理쒖옱???꾩??섎? |
| 11:15-11:35 |
Optimal Choice of Beta Blockers and ARBs for AMI
Patients |
?쒖＜???깃퇏愿�?섎? |
| 11:35-11:55 |
How to Treat ? : Atrial Fibrillation in STEMI
Patients |
諛뺥삎??怨꾨챸?섎? |
| 11:55-12:15 |
What?셲 a Novel Protein Cocktail for Protection of
Reperfusion Injury in AMI |
源�?숈슫/異⑸턿?섎? |
| 12:15-12:20 |
Discussion |
| CHF 2 [April 17, 10:55-12:20 Rm.201] |
|
| Heart Failure : Factors for the Progression
and Reversal of Clinical Course |
| Chairperson |
|
| Panel |
|
| 10:55-11:10 |
Myocardial Ischemia in HFrEF |
?쒖꽦???쒕┝?섎? |
| 11:10-11:25 |
Reverse Remodeling of Heart Failure |
TBA |
| 11:25-11:40 |
Atrial Fibrillation and Decompensated Heart
Failure |
源�?깊솚/媛�?⑤┃?섎? |
| 11:40-12:05 |
Keynote Lecture: Heart Failure: The Recent
Advances |
John J.V. Mcmurray/
Glasgow Univ.,
UK |
| 12:05-12:20 |
Discussion |
| Imaging 2 [April 17, 10:55-12:20 Rm.205] |
|
| Recent Controversial Issues in
Cardiovascular Perfusion Imaging |
| Chairperson |
|
| Panel |
|
| 10:55-11:20 |
Myocardial CT Perfusion: The New One-Stop Shop for
Ischemic Heart Disease |
?묐룞???몄궛?섎? |
| 11:20-11:45 |
CMR Perfusion: The Prime for Myocardial Perfusion
Imaging |
異붽린??遺�?곗쓽?� |
| 11:45-11:55 |
Rebuttal by Presenter 1 |
| 11:55-12:05 |
Rebuttal by Presenter 2 |
| 12:05-12:20 |
Discussion |
| Scientific Session 1 [April 17, 12:30-13:10
Rm.103] |
|
| |
| Scientific Session 2 [April 17, 12:30-13:10
Rm.104] |
|
| |
| Scientific Session 3 [April 17, 12:30-13:10
Rm.205] |
|
| |
| Suh, Soon-Kyu Memorial Lecture [April 17,
14:30-15:15 Rm.103] |
|
| Chairperson |
|
| 14:30-15:10 |
Diet, Herbs and Supplements: What Works |
C. Noel Bairey Merz/
Cedars-Sinai
Medical Center, USA |
| 15:10-15:15 |
Discussion |
| Plenary Session [April 17, 15:15-16:00 Rm.103]
|
|
| Chairperson |
|
| 15:15-15:55 |
ARNI: A True Paradigm Shift in HF Management |
John McMurray/
Glasgow Univ.,
UK |
| 15:55-16:00 |
Discussion |
| Arrhythmia 2 [April 17, 16:15-17:45 Rm.104] |
|
| Novel Approaches to
Arrhythmia |
| Chairperson |
|
| Panel |
|
| 16:15-16:35 |
Non-Antiarrhythmic Drugs for Arrhythmia Control |
源�吏꾨같/寃쏀씗?섎? |
| 16:35-16:55 |
Subcutaneous ICD |
諛뺢꼍誘??깃퇏愿�?섎? |
| 16:55-17:15 |
Mobile Healthcare Technology |
源�?ㅻ뀈/怨꾨챸?섎? |
| 17:15-17:35 |
Neural Modulation |
?ㅼ꽭???쒖슱?섎? |
| 17:35-17:45 |
Discussion |
| Allied Professional 1 [April 17, 16:15-17:45
Rm.201] |
|
| Cardiac Arrhythmia
Diagnostics |
| Chairperson |
|
| 16:15-16:45 |
SVT vs. VT Differential Diagnosis |
諛뺤쥌???숈븘?섎? |
| 16:45-17:15 |
Tilt-Table Test : Protocols and Diagnostic
Efficacy |
諛뺤젙???쇱꽦?쒖슱蹂묒썝 |
| 17:15-17:45 |
How to Reduce Radiation in Cath. Lab? |
媛뺤???怨좊??덉븫蹂묒썝 |
| Womens Heart Disease [April 17, 16:15-17:45
Rm.205] |
|
| Women and Ischemic Heart Disease
(IHD) |
| Chairperson |
|
| Panel |
|
| 16:15-16:45 |
Detection, Diagnosis and Management |
C. Noel Bairey Merz/Cedars-Sinai
Medical Center, USA |
| 16:45-17:05 |
Pathophysiology : Vasospasm and Microvascular
Angina |
諛뺤꽦誘?怨좊젮?섎? |
| 17:05-17:25 |
Gender-Specific Risk Factors for IHD |
源�?숇졊/?쒖슱?섎? |
| 17:25-17:45 |
Discussion |
| Arrhythmia 3 [April 18, 08:30-10:00 Rm.104] |
|
| Tips in AF Management |
| Chairperson |
|
| Panel |
|
| 08:30-08:50 |
Aspirin for Low Risk AF Patients: Is It Beneficial or
Harmful? |
?닿꼍???꾨턿?섎? |
| 08:50-09:10 |
Antiarrhythmic Drug: Case-by-Case Choice |
李⑦깭以�/怨좎떊?섎? |
| 09:10-09:30 |
Strategy for Persistent AF Ablation |
諛뺥씗???곗꽭?섎? |
| 09:30-09:50 |
Patient Selection Criteria for LAA Occlusion |
?⑥쁺洹??깃퇏愿�?섎? |
| 09:50-10:00 |
Discussion |
| Allied Professional 2 [April 18, 08:30-10:00
Rm.201] |
|
| Cardiac Devices |
| Chairperson |
|
| 08:30-09:00 |
Whats New in CIEDs? |
諛뺥삎??怨꾨챸?섎? |
| 09:00-09:30 |
LA Appendage Closure Device : When and How? |
?꾪솉??怨좊젮?섎? |
| 09:30-10:00 |
Temporary Pacemaker : Programming and Trouble
Shooting |
?쒕몢???쒖슱?꾩궛蹂묒썝 |
| CHD 1 [April 18, 08:30-10:00 Rm.203] |
|
| Natural and Unnatural History of Adults
With Congenital Heart Disease (ACHD) |
| Chairperson |
|
| Panel |
|
| 08:30-08:50 |
Prevalence of ACHD in Current Era |
?뺤“???곗꽭?섎? |
| 08:50-09:10 |
Trends in Survival and Mortality of ACHD |
湲명솉??異⑸궓?섎? |
| 09:10-09:30 |
Cardiopulmonary Variables During Exercise in Adult
Patients With Congenital Heart Disease |
Hideo Ohuchi/National Cardiovascular
Center, Japan |
| 09:30-09:50 |
Quality of Life in ACHD |
諛뺤듅???깃퇏愿�?섎? |
| 09:50-10:00 |
Discussion |
| Hypertension 1 [April 18, 08:30-10:00 Rm.205]
|
|
| Hypertension in the Young |
| Chairperson |
|
| 08:30-08:50 |
Epidemiology and Etiology |
吏꾨룞洹??쒖쿇?μ쓽?� |
| 08:50-09:10 |
Particularities of Diagnosis and Risk Assessment in the
Young |
?꾩긽??媛�?⑤┃?섎? |
| 09:10-09:30 |
When and How to Treat Hypertension in the Young |
?≪쁺???쒖슱?섎? |
| 09:10-09:50 |
Hypertension in Young Women: From Pre-Conception
Through Pregnancy |
議곗?二?媛�?⑤┃?섎? |
| Basic Research 1 [April 18, 10:15-11:45 Rm.201]
|
|
| Inflammation |
| Chairperson |
|
| Panel |
|
| Panel |
|
| 10:15-10:30 |
Bradycardia: Hemodynamic Impact and Revisited Pacemaker
Indication in Children |
議곕???遺�?곗쓽?� |
| 10:30-10:45 |
Pacemaker Programming and Follow up in Children and CHD
Patients |
源�?ы뼢/寃쎈턿?섎? |
| 10:45-11:00 |
Nonsurgical Management of Arrhythmia in Adult CHD |
源�?④퇏/?곗꽭?섎? |
| 11:00-11:15 |
Surgical Management of Arrhythmia in Adult CHD: |
源�?낇븳/?쒖슱?섎? |
| 11:15-11:30 |
Sudden Cardiac Death Prevention in Children and CHD
Patients |
?덉?/?깃퇏愿�?섎? |
| 11:30-11:45 |
Discussion |
| Hypertension 2 [April 18, 10:15-11:45 Rm.205]
|
|
| Hot Issues in Hypertension |
| Chairperson |
|
| 10:15-10:35 |
Current Controversies in Blood Pressure Assessment |
?좎쭊???쒖뼇?섎? |
| 10:35-10:55 |
Importance of Blood Pressure Variabilitys |
?뺤쨷??議곗꽑?섎? |
| 10:55-11:15 |
Blood Pressure Control and Subclinical Organ Damage
Regression |
?좊???媛�泥쒖쓽?� |
| 11:15-11:35 |
Recent Update of Renal Denervation Therapy |
源�蹂묎레/?곗꽭?섎? |
| Scientific Session 4 [April 17, 12:30-13:10
Rm.103] |
|
| |
| Scientific Session 5 [April 17, 12:30-13:10
Rm.104] |
|
| |
| Scientific Session 6 [April 17, 12:30-13:10
Rm.205] |
|
| |
| Arrhythmia 4 [April 18, 14:00-15:30 Rm.103] |
|
| Special Issues in ICD and CRT |
| Chairperson |
|
| Panel |
|
| 14:00-14:20 |
Is This Myocardial Disease Reversible or Not? |
理쒖쭊???깃퇏愿�?섎? |
| 14:20-14:40 |
How to Identify Optimal ECG Patterns for CRT |
源�?�???명븯?섎? |
| 14:40-15:00 |
Outcome of Brugada Syndrome After ICD Implantation |
?④린蹂??몄궛?섎? |
| 15:00-15:20 |
ICD Optimal Programming |
?뺣낫???곗꽭?섎? |
| 15:20-15:30 |
Discussion |
| Mobile Healthcare in CVD [April 18, 14:00-15:30
Rm.201] |
|
| Perspectives of Remote Healthcare in
Cardiovascular Diseases |
| Chairperson |
|
| 1 |
The Concept of Mobile Healthcare |
TBA |
| 2 |
The Experience in Mobile Healthcare |
TBA |
| 3 |
Mobile Healthcare |
TBA |
| CHD 3 [April 18, 14:00-15:30 Rm.203] |
|
| Long-Term Post-Operative Follow up of
Congenital Heart Disease (CHD) |
| Chairperson |
|
| Panel |
|
| 14:00-14:15 |
Neurodevelopmental Outcome and Follow-up Protocol |
?댁????깃퇏愿�?섎? |
| 14:15-14:30 |
Exercise Guideline and Rehabilitation Programs |
?깆????깃퇏愿�?섎? |
| 14:30-14:55 |
Changes of Cardiac Autonomic Nervous System |
Hideo Ohuchi/
National
Cardiovascular Center, Japan |
| 14:55-15:10 |
Long Term Post-op Follow up Protocol for Fontan
Circulation |
源�?섏쭊/嫄닿뎅?섎? |
| 15:10-15:25 |
Long Term Post-op Follow up for the Complex Two
Ventricle Repair (Rastelli Operation in TGA Patients |
?μ냼???몄쥌蹂묒썝 |
| 15:25-15:30 |
Discussion |
| Arrhythmia 5 [April 18, 15:45-17:15 Rm.104] |
|
| Practical Issues in Clinic |
| Chairperson |
|
| Panel |
|
| 15:45-16:05 |
Alcohol and Caffeine Abstinence for Patients With AF:
Is it Essential? |
源�?⑦샇/?먭킅?섎? |
| 16:05-16:25 |
Asymptomatic WPW Syndrome: Observation or
Ablation? |
諛뺥삎???꾨궓?섎? |
| 16:25-16:45 |
Is Atrial Flutter a Close Relative to AF? |
諛뺤긽???몄쥌蹂묒썝 |
| 16:45-17:05 |
Management for a Girl With LQTS and Sinus
Bradycardia |
?⑷탳???꾩＜?섎? |
| 17:05-17:15 |
Discussion |
| Basic Research 2 [April 18, 15:45-17:15 Rm.201]
|
|
| Signaling Mechanisms |
| Chairperson |
|
| Panel |
|
| 15:45-16:05 |
Transcriptional Regulation of Vascular Network
Formation by SOX F Members |
源�?몄?/KAIST |
| 16:05-16:25 |
Roles of Orphan Nuclear Receptors in Cardiac
Hypertrophy |
援?쁽/?꾨궓?섎? |
| 16:25-16:45 |
Role of Formyl Peptide Receptor 2 in Therapeutic
Angiogenesis |
源�?ы샇/遺�?곗쓽?� |
| 16:45-17:05 |
ROS signaling in Atherosclerosis via Impaired
Autophagy |
?ㅺ뎄???댄솕?щ? |
| 17:05-17:15 |
Discussion |
| CHD 4 [April 18, 15:45-17:15 Rm.203] |
|
| New Medication &
Treatment |
| Chairperson |
|
| Panel |
|
| 15:45-16:05 |
New Cardiovascular Drugs for Pediatric Heart
Failure |
?섍린??怨좊젮?섎? |
| 16:05-16:25 |
New Drugs for Pulmonary Hypertension
|
源�湲곕쾾/?쒖슱?섎? |
| Pros & Cons : Late Failure of Fontan
Circulation |
| 16:25-16:45 |
- Fontan Takedown, and Conversion to Two Ventricle |
?댁갹???몄쥌蹂묒썝 |
| 16:45-17:05 |
- Heart Transplantation |
TBA |
| 17:05-17:15 |
Discussion |
| Vascular Disease [April 18, 15:45-17:15 Rm.205]
|
|
| Contribution of Arterial Stiffness to the
Development of Hypertension: From Bench to Bedside |
| Chairperson |
|
| 15:45-16:15 |
Aortic Stiffness, Blood Pressure Progression and
Incident Hypertension |
Boutouyrie Pierre/ HEGP Hopital
Europeen, France |
| 16:15-16:35 |
Can Exercise Reduce Arterial Stiffness in
Hypertensives? |
?쒖꽭???쒖슱?쒕┰?� |
| 16:35-16:55 |
Vascular calcification: A Novel Mechanism for Aortic
Stiffness in Hypertension |
源�?묒＜/怨좊젮?섎? |
| 16:55-17:15 |
Interplay of Inflammation and Oxidative Stress in
Aortic Stiffening |
諛뺤꽦???곗꽭?섎? |
| KSE 1 [April 17, 14:30-16:00 Rm.104] |
|
| Issues & Updates in Valvular Heart
Disease |
| Chairperson |
?ъ셿二? 梨꾩꽦泥?/td> |
| 14:30-14:50 |
Bicuspid Aortic Valve: Pathogenesis & Clinical
Significance |
?≪옱愿�/?몄궛?섎? |
| 14:50-15:10 |
Paradoxical Low Flow Low Pressure Aortic Stenosis:
Causes & Prognostic Implication |
源�?⑹쭊/?쒖슱?섎? |
| 15:10-15:30 |
Secondary Mitral Regurgitation: Severity Assessment
& Management |
沅뚯?/?명븯?섎? |
| 15:30-15:50 |
Marfan Syndrome: Diagnosis & Management |
諛뺤듅???깃퇏愿�?섎? |
| 15:50-16:00 |
Discussion |
| KSE 2 [April 17, 16:15-17:45 Rm.103] |
|
| Learning From Cases &
Echocardiography |
| Chairperson |
?κ꼍?? ?좎???/td> |
| Panel |
源�?좎옱, ?쒖젙?? 理쒖쓽??/td> |
| 16:15-16:35 |
Mitral Valve Disease |
諛뺥깭???숈븘?섎? |
| 16:35-16:55 |
Aortic Valve Disease |
諛뺤꽦吏�/?깃퇏愿�?섎? |
| 16:55-17:15 |
Tricuspid Valve Disease |
?띻렇猷??곗꽭?섎? |
| 17:15-17:35 |
Infective Endocarditis |
媛뺣뜒???몄궛?섎? |
| 17:35-17:45 |
Discussion |
| KSE 3 [April 18, 10:15-11:45 Rm.104] |
|
| Issue & Updates in Myocardial &
Pericardial Disease |
| Chairperson |
?먮??? 源�湲곗떇 |
| 10:15-10:35 |
Cardiac Amyloidosis: Diagnostic Tools &
Management |
?댁듅???쒖슱?섎? |
| 10:35-10:55 |
Hypertrophic Cardiomyopathy: Differential Diagnosis
& Management |
源�?곗떇/寃쏀씗?섎? |
| 10:55-11:15 |
Tuberculous Pericarditis: Diagnosis &
Management |
?≪쥌誘??몄궛?섎? |
| 11:15-11:35 |
Constrictive Pericarditis: Transient & Reversible
Constriction |
源�怨꾪썕/?꾨궓?섎? |
| 11:35-11:45 |
Discussion |
| KSE 4 [April 18, 14:00-15:30 Rm.205] |
|
| Learning from Cases &
Echocardiography |
| Chairperson |
諛뺤쥌異? ?ㅽ샇以?/td> |
| Panel |
源�?깊솚, ?댁꽑?? 理쒖젙??/td> |
| 14:00-14:20 |
Hypertrophic Cardiomyopathy |
?묐룞??寃쎈턿?섎? |
| 14:20-14:40 |
Stress Cardiomyopathy |
?쒖꽦???쒕┝?섎? |
| 14:40-15:00 |
Myocarditis/Myocardial Infiltration |
議곌뎄???쒖슱?섎? |
| 15:00-15:20 |
Pericardial Disease |
?댁긽泥??깃퇏愿�?섎? |
| 15:20-15:30 |
Discussion |
| KSIC 1 [April 18, 08:30-9:50 Rm.103] |
|
| For Young Interventionist : Basic
Techniques for Coronary Intervention |
| Chairperson |
?묒＜?? 梨꾩씤??/td> |
| Panel |
源�湲곗꽍, 諛뺤쥌?? 諛뺥썕以�, ?꾧뎅吏? ?띿쁺以� |
| 08:30-08:42 |
Puncture Technique and Hemostasis (Femoral and
Radial) |
源�?곷?/異⑸턿?섎? |
| 08:42-08:54 |
Selection of Guiding Catheter According to Artery |
?좊룞???곗꽭?섎? |
| 08:54-09:06 |
Selection of Guidewire According to Lesion |
源�?뱁솚/?꾩??섎? |
| 09:06-09:18 |
Optimal Stenting for Bifurcated Lesion |
?≪쁺鍮??깃퇏愿�?섎? |
| 09:18-09:30 |
Optimal Stenting for Calcified Tortuous Lesion |
?ㅽ쁺以�/怨꾨챸?섎? |
| 09:30-09:50 |
Discussion |
| KSIC 2 [April 18, 10:15-11:45 Rm.103] |
|
| How Can We Decrease Infarction
Size? |
| Chairperson |
?덊깭?? 源�蹂묒삦 |
| Panel |
媛뺤썒泥? 媛뺥쁽?? 沅뚭린?? ?좎듅湲? ?ㅼ쁺??/td> |
| 10:15-10:35 |
Ischemic Injury and Reperfusion Injury |
?쒖젙???쒖슱?섎? |
| 10:35-10:55 |
Drug Therapy |
?댁옣??寃쎈턿?섎? |
| 10:55-11:15 |
Interventional Treatment |
?대큺湲?媛뺤썝?섎? |
| 11:15-11:35 |
Cell and Future Therapy |
諛곗옣??異⑸턿?섎? |
| 11:35-11:45 |
Discussion |
| KSIC 3 [April 18, 14:00-15:30 Rm.104] |
|
| Limitations ; What You Have to
Know |
| Chairperson |
?곸듅?? 源�?먯씪 |
| Panel |
援щ낯沅? 源�蹂묎레, ?덉쁺洹? ?댁옱?? ?꾩쁺??/td> |
| 14:00-14:17 |
Limitation of CAG, What You Have to Know |
梨꾩젣嫄??꾨턿?섎? |
| 14:17-14:34 |
Limitation of IVUS, What You Have to Know |
?대큺???�援ы뙆?곕쭏蹂묒썝 |
| 14:34-14:51 |
Limitation of OCT, What You Have to Know |
理쒖냼???꾩＜?섎? |
| 14:51-15:08 |
Limitation of FFR, What You Have to Know |
?꾩????몄젣?섎? |
| 15:08-15:30 |
Discussion |
| KSIC 4 [April 18, 15:45-17:15 Rm.103] |
|
| What Is OMT (Optimal Medical Therapy) in
Real World Practice |
| Chairperson |
?뺣챸?? 諛뺥뿄??/td> |
| Panel |
源�?곹쁽, ?섎뱷?? 諛곗옣?? 二쇳삎以�, ?덉듅??/td> |
| 15:45-16:02 |
How to Treat a Patient With Silent Nonobstructive
Coronary Artery Disease in Coronary CT |
?좎긽???쇱궛蹂묒썝 |
| 16:02-16:19 |
How to Treat a Patient Intolerant to Aspirin After PCI:
Short-Term and Long-Term Therapy |
?쒖＜???깃퇏愿�?섎? |
| 16:19-16:36 |
How to Treat a Patient Intolerant to Moderate Intensity
Statin Who Is Proven ASCVD |
?ㅺ꼍???먭킅?섎? |
| 16:36-16:53 |
How to Treat a Patient Without Chest Pain After PCI ;
Beta-Blocker First or RAS Inhibitor First? |
?묓깭???몄젣?섎? |
| 16:53-17:15 |
Discussion |
![吏�吏덈룞留? src=]()
| KSLA 1 [April 17, 09:15-10:45 Rm.203] |
|
| Vascular Research in Cardiovascular
Disease |
| Chairperson |
理쒖쁺湲? 源�?묓븯 |
| Panel |
媛뺤떊?? 源�?ㅼ뿰, 諛뺤꽦?? ?좊룞?? 議곌꼍??/td> |
| 09:15-09:40 |
Immunosenescence and Vascular Aging |
?좎쓽泥??쒓뎅怨쇳븰湲곗닠??/td> |
| 09:40-10:05 |
Role of PCSK9 in Uptake and Degradation of LDL
Particles |
諛뺤긽???곗꽭?섎? |
| 10:05-10:30 |
Metabolomic Profiling for the Metabolism and
Atherogenesis |
?⑷툑???쒓뎅湲곗큹怨쇳븰吏�?먯뿰援ъ썝 |
| 10:30-10:45 |
Discussion |
| KSLA 2 [April 17, 10:55-12:20 Rm.203] |
|
| Metabolism and Brain |
| Chairperson |
?좏쁽?? ?쒗솉??/td> |
| Panel |
源�?⑹옱, 諛뺢킅?? ?ㅺ뎄?? ?댁??? 理쒖꽦??/td> |
| 10:55-11:20 |
Metabolic Actions of Rho-Kinase in Periphery and
Brain |
Young-Bum Kim/Harvard Univ.,
USA |
| 11:20-11:45 |
Possible Role of Low-dose PPAR-款 Agonist through LRP1
Regulation in Alzheimer?셲 Disease |
李⑤큺???곗꽭?섎? |
| 11:45-12:10 |
The Role of Free Fatty Acid in Ischemic Stroke |
?쒖슦洹?怨좊젮?섎? |
| 12:10-12:20 |
Discussion |
| KSLA 3 [April 17, 14:30-16:00 Rm.203] |
|
| Update of Cholesterol Treatment Guidelines
|
| Chairperson |
源�移섏젙, 諛뺢꼍??/td> |
| Panel |
源�?�以? 源�蹂묒쭊, 源�?⑹꽍, ?↔린?? ?댁긽??/td> |
| 14:30-14:55 |
Review of Updated Korean Cholesterol Treatment
Guidelines and Others |
源�?곹쁽/?쒖슱?섎? |
| 14:55-15:20 |
Should We Apply Subclinical Atherosclerosis as a Marker
for CVD Risk? |
?쒓린???몄궛?섎? |
| 15:20-15:45 |
CVD Risk Calculators: What Are Their Positions in the
Clinical Practice? |
?뺤갹???몄궛?섎? |
| 15:45-16:00 |
Discussion |
| KSLA 4 [April 17, 16:15-17:45 Rm.203] |
|
| Special Debate Session: "A Patient with
Type 2 Diabetes without Any History of Cardiovascular Disease and Already on
Statin with LDL-C < 100 mg/dL, but Still High TG and Low HDL-C. Whats Next?"
|
| Chairperson |
?대Ц洹?/td> |
| Panel |
源�?ы깮, 源�?쒖쭊, ?쒖??? 議곗긽?? 理쒖냼??/td> |
| 16:15-16:25 |
Introduction |
?대Ц洹??깃퇏愿�?섎? |
| 16:25-16:50 |
Increase the Statin Dosage |
?깃린泥??깃퇏愿�?섎? |
| 16:50-17:15 |
Add Fibrates |
源�?깅옒/媛�?⑤┃?섎? |
| 17:15-17:40 |
Discussion |
| 17:40-17:45 |
Voting and
Conclusion |
2015-03-02 오후 4:05:45, 조회수 : 1853
|